Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic diseases.
Stock is 

Investor Overview

Analyst Coverage

Firm Analyst
Canaccord Genuity
John Newman Ph.D.
Mohit Bansal
Chris Shibutani M.D.
Goldman Sachs
Salveen Richter
Guggenheim Partners
Michael Schmidt Ph.D.
JP Morgan
Anupam Rama
Leerink Partners
Andrew Berens M.D.
Needham & Company
Chad Messer Ph.D.
Oppenheimer & Co.
Mark Breidenbach Ph.D.
Piper Jaffray & Co
Tyler Van Buren

Stock Information

Copyright West LLC. Minimum 15 minutes delayed.